1 reply to this topic

[Sneezy12]

http://medicalxpress...nt-chronic.html    Frank

[Trey]

It seems premature to combine bosutinib with anything since it has not proven itself against CML.  And especially combining bosutinib with danusertib (a pan-aurora kinase inhibitor) is a bit odd.  The Aurora kinase inhibitors have a questionable history, and some have been abandoned after severe impact on the heart.  I personally think the pan-aurora kinase inhibitors should only be used where there is no other option.  For the gatekeeper mutation (T315i) there is Ponatinib, which should be used first.